Edition:
India

Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

16.37USD
16 Aug 2019
Change (% chg)

$0.26 (+1.61%)
Prev Close
$16.11
Open
$16.15
Day's High
$16.51
Day's Low
$15.94
Volume
24,394
Avg. Vol
51,984
52-wk High
$34.65
52-wk Low
$12.59

Summary

Name Age Since Current Position

Thomas Crockett

43 2016 Chief Executive Officer, Director

Benjamin Palleiko

52 2019 Chief Financial Officer, Chief Business Officer

Andreas Maetzel

54 2017 Senior Vice President, Medical

Edward Feener

57 2016 Chief Scientific Officer

Christopher Yea

55 2016 Chief Development Officer

Martin Edwards

62 2019 Director

Brian Pereira

59 2019 Director

Daniel Soland

61 2019 Director

Albert Cha

46 2007 Independent Director

Arnold Oronsky

78 2016 Independent Director

Edward Unkart

68 2014 Independent Director

Biographies

Name Description

Thomas Crockett

Mr. Thomas Andrew Crockett is Chief Executive Officer and Director of the Company. He has served as a member of our Board and as our Chief Executive Officer since November 2016 and as a director and CEO of our wholly owned subsidiary, KalVista Pharmaceuticals Limited, since inception in 2011. From 2010 until November 2015, Mr. Crockett was the Chief Executive Officer and member of the board of directors of Vantia Ltd., where he served as Vice President of Business Development prior to his promotion. He continues to sit on the board of directors. Mr. Crockett has also held various senior management positions including Vice President of Business Development and Director of Clinical and Regulatory Affairs in biotech and specialty pharmaceutical companies in the United States and United Kingdom. Mr. Crockett received a B.A. from the University of Utah and M.B.A. from The Wharton School, University of Pennsylvania, with a major in finance.

Benjamin Palleiko

Mr. Benjamin L. Palleiko is Chief Financial Officer, Chief Business Officer of KalVista Pharmaceuticals, Inc. Mr. Palleiko was hired as Chief Financial Officer of KalVista Limited in August 2016 and was appointed as our Chief Financial Officer in November 2016 in connection with the reverse acquisition transaction. Prior to joining us, Mr. Palleiko was a Managing Director of H.C. Wainwright & Co. LLC since January 2015. Mr. Palleiko also co-founded a private oncology drug development company, Cielo Therapeutics, Inc., in July 2012. Mr. Palleiko served as Chief Financial Officer of Nostrum Pharmaceuticals LLC, a specialty generic pharmaceuticals company, from January 2012 to December 2013. He previously was Senior Vice President and Chief Financial Officer of Ore Pharmaceutical Holdings Inc. and Penwest Pharmaceuticals Co. Earlier in his career Mr. Palleiko was an investment banker with the firms Robertson Stephens and SunTrust Robinson Humphrey. Mr. Palleiko holds a B.A. in Quantitative Economics from Tufts University and an M.B.A. in Finance and M.A. in International Relations from the University of Chicago. He served as a Naval Aviator in the U.S. Navy.

Andreas Maetzel

Dr. Andreas Maetzel M.D. Ph.D., is the Senior Vice President, Medical of the Company, since march 2017. Dr. Maetzel was most recently Vice President, Global Medical Affairs at BioCryst Pharmaceuticals from August 2014 to February 2017. Prior to that he was Vice President, Clinical Development & Regulatory Affairs at Cornerstone Therapeutics Inc from May 2013 to February 2014. From September 2011 to April 2013, Dr. Maetzel held a clinical development role at BioCryst. He previously held positions in health technology assessment strategy at Amgen and in strategy consulting. He is Visiting Scientist at the University Hospital Zurich and Charité Hospital Berlin, and maintains an appointment as Adjunct Professor, Institute for Health Policy, Management & Evaluation, University of Toronto. Dr. Maetzel obtained both a Ph.D. and M.Sc. in Clinical Epidemiology from the University of Toronto and a Dr. Med. at the University of Hannover, Germany.

Edward Feener

Mr. Edward P. Feener Ph.D. is the Chief Scientific Officer of the Company. Edward P. Feener, Ph.D., is a scientific co-founder of KalVista and joined as our Chief Scientific Officer in November 2016. Previously, Dr. Feener was an Associate Professor of Medicine at Harvard Medical School and Senior Investigator in the Section on Vascular Cell Biology at Joslin Diabetes Center from July 1989 to October 2016. He has more than 27 years of research experience in vascular biology and diabetic complications. His laboratory identified novel mechanisms of action for the plasma kallikrein system, which are implicated in diabetic macular edema, vascular injury, and angioedema.

Christopher Yea

Mr. Christopher M. Yea, Ph.D., is the Chief Development Officer of of the Company. since November 2015 and became our Chief Development Officer as of November 2016 in connection with the reverse acquisition transaction. Prior to joining us, he was the Chief Operating Officer at Vantia, Ltd. from its spin-out from Ferring Pharmaceuticals in 2008, until November 2015. Prior to the spin-out of Vantia, Dr. Yea led the Biology group and was responsible for transition of candidates into development at Ferring Pharmaceuticals. Following post-doctoral work he spent several years at Roussel-UCLAF and Hoechst Marion Roussel. Dr. Yea holds a B. Sc. and Ph.D. in Biochemistry from the University of Bristol, UK.

Martin Edwards

Hr. Martin Edwards is Director of the Company. Dr. Edwards is Senior Partner (part time) at Novo Ventures and previously served as Chair of KalVista when it was a privately held company. He is Chairman of the Board of Directors of Vantia Therapeutics Ltd., and a member of the Board of Directors of Verona Pharma, Nuvelution Pharmaceuticals Inc, Harmony Biosciences Inc, Inozyme Pharma Inc, F2G Ltd, and Karus Therapeutics Ltd. Prior to joining Novo Ventures, Dr. Edwards was the CEO of ReNeuron Holdings, and formerly Corporate VP and Head of Drug Development for Novo Nordisk A/S where he was responsible for all aspects of pre-clinical and clinical drug development. Earlier, he worked for six years in the USA first as VP Pharmacology and Medical Affairs of ZymoGenetics Inc. in Seattle, and then as Senior VP for Medical Affairs at Novo Nordisk in Princeton, NJ. Dr. Edwards trained in physiology and medicine in Manchester UK. He was elected as a Member of the Royal Colleges of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and holds an MBA from the University of Warwick.

Brian Pereira

Dr. Brian J. G. Pereira M.D. is Director of the company. Prior to his role at AMAG, Brian held senior roles at Tufts Medical Center including President and CEO of a Tufts Medical Center Physician Organization and interim COO. Brian is Chairman of the Board of Directors of Africa Healthcare Network and of NephroPlus Ltd. He has previously served on the Board of several private and public companies, was the Chairman of the Board of the Harvard-MIT Biomedical Enterprise Program and President and Board member of the National Kidney Foundation. Brian is an Adjunct Professor of Medicine at Tufts University School of Medicine and has authored over 200 published scientific articles. He received his medical degree (MBBS) from St. John's Medical College, MD (Medicine) and DM (Nephrology) from the Post Graduate Institute, and MBA from Kellogg School of Management at Northwestern University.

Daniel Soland

Mr. Daniel B. Soland is Director of the company. Mr. Soland most recently served as the Chief Executive Officer of uniQure N.V. and Senior Vice President and Chief Operating Officer of ViroPharma.

Albert Cha

Dr. Albert Cha, M.D. Ph.D. is an Independent Director of the Company. Dr. Cha has served as a member of our Board since the consummation of the Carbylan Therapeutics, Inc. transaction in 2016. Dr. Cha served as a member of the Carbylan board of directors starting in November 2007. In September 2000, Dr. Cha joined Vivo Capital, a healthcare investment firm, where he has served in various positions, most recently as a Managing Partner. Dr. Cha currently serves as a member of the boards of directors of Biohaven Pharmaceutical Holding Company Ltd., Ascendis Pharma A/S and several privately-held biotechnology and medical device companies. During the past five years, he also served as a member of the boards of directors of Aclaris Therapeutics, Inc., Sierra Oncology, Inc. (formerly ProNAi Therapeutics, Inc.) and AirXpanders, Inc. Dr. Cha received a B.S. and an M.S. from Stanford University and an M.D. and a Ph.D. from the University of California at Los Angeles. We believe Dr. Cha is qualified to serve on our Board because of his medical background, venture capital experience and significant experience serving as a director of other life sciences companies.

Arnold Oronsky

Mr. Arnold L. Oronsky, Ph.D., is Independent Director of the Company, since November 2016. Dr. Oronsky has served as a member of our Board since November 2016. Dr. Oronsky has been a full-time member of InterWest’s healthcare team since 1994, where he currently serves as a Senior Partner. In addition to being a Senior Partner at InterWest, Dr. Oronsky also serves as a Senior Lecturer in the Department of Medicine at Johns Hopkins Medical School. He is a member of the board of directors of Dynavax Technologies, TESARO and a number of private pharmaceutical companies. Dr. Oronsky was formerly Vice President for Discovery Research for the Lederle Laboratories division of American Cyanamid Company where he directed all of the research for new drugs and supervised approximately three hundred employees. Dr. Oronsky holds a Ph.D. in Immunology from Columbia University and has published over 125 scientific articles. We believe Dr. Oronsky is qualified to serve on our Board because of his lengthy experience in the biotech industry as an investor and public company Board member.

Edward Unkart

Mr. Edward W. Unkart, CPA is an Independent Director of the Company. Mr. Unkart served as a member of the board of directors of XTENT, a publicly traded manufacturer of drug-eluting stent systems, where he was the chair of the company’s audit committee and a member of the nominating and governance committee. From October 2004 to June 2009, Mr. Unkart served as a member of the board of directors of VNUS Medical Technologies, a publicly traded medical device company, where he was the Chair of the company’s audit committee and a member of the compensation committee. From January 2005 to December 2008, Mr. Unkart served as Vice President of Finance and Administration and Chief Financial Officer of SurgRx, a manufacturer of medical devices. Mr. Unkart is a Certified Public Accountant and holds a B.S. and an M.B.A. from Stanford University. We believe Mr. Unkart is qualified to serve on our Board because of his finance and accounting expertise and education and his experience gained through his board and officer positions at other life sciences companies.